Showing 6721-6730 of 8888 results for "".
- Bristol Myers Squibb’s New Sotyktu Campaign Reveals the Plain Truth About Living With Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibbs-new-clear-understanding-campaign-reveals-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2461914/Bristol Myers Squibb is rolling
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for
- Replimune, Incyte Enter Into Clinical Trial Collaboration And Supply Agreement To Evaluate RP1 and INCB99280 in CSCChttps://practicaldermatology.com/news/replimune-incyte-enter-into-clinical-trial-collaboration-and-supply-agreement-to-evaluate-rp1-and-incb99280-in-cscc/2461908/Replimune Group, Inc. and Incyte are collaborating to a study RP1 in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor, in cutaneous squamous cell carcinoma (CSCC) and in other cancer types,
- RoC Skincare Expands The Look Forward Project to Instill Optimism Among the Next Generationhttps://practicaldermatology.com/news/roc-skincare-expands-the-look-forward-project-to-instill-optimism-among-the-next-generation/2461905/RoC Skincare is expanding The RoC Look Forward Project in partnership with Sarah Jessica Parker. The initiative was first launched in 2022 to celebrate the power of optimism and its positive impact on long-term health and wellbeing. Now, the Look Forward
- Another FDA Nod for SkinStylus Microneedling Device: Facial Acne Scarshttps://practicaldermatology.com/news/another-fda-nod-for-skinstylus-microneedling-device-facial-acne-scars/2461904/
- AAD, Janssen, and Kenvue Mentor Next Generation of Dermatologistshttps://practicaldermatology.com/news/aad-janssen-and-kenvue-mentor-next-generation-of-dermatologists/2461884/As part of
- AI in Action: Perfect Corp. Debuts New Skin Type Detection Technologyhttps://practicaldermatology.com/news/ai-in-action-perfect-corp-debuts-new-skin-type-detection-technology/2461883/
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- AD Pipeline Watch: Alphyn Biologics’ Topical AB-101Shows Promise in Phase 2a Studyhttps://practicaldermatology.com/news/ad-pipeline-watch-alphyn-biologics-topical-ab-101shows-promise-in-phase-2a-study/2461852/
- VisualDx, Vaseline Join Forces to Advance Education on Treating Skin of Colorhttps://practicaldermatology.com/news/visualdx-vaseline-join-forces-to-advance-education-on-treating-skin-of-color/2461817/VisualDx and